Galderma stock trades at EUR 207.45; Relfydess receives China approval
Published on 10/25/2026 at 17:29 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWSChina approval and coming session
- On October 23, 2026, Galderma announced China approval for Relfydess, which is authorized in more than 35 markets.
- Galderma stock trades at EUR 207.45 at 5:27 p.m. CEST at Lang & Schwarz on October 25, 2026.
- The next Xetra session is scheduled for October 26, 2026.
On October 23, 2026, Galderma announced that China’s National Medical Products Administration had approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, according to the company’s press release. Galderma stock was at EUR 207.45 at 5:27 p.m. CEST on October 25, 2026, according to Lang & Schwarz.
Market context: Market report SMI.
Weekend trading
Lang & Schwarz quoted Galderma at EUR 207.45 in weekend trading at 5:27 p.m. CEST on October 25, 2026. The company’s shares are listed on SIX under the ticker GALD. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Galderma stock.
The week in figures
The latest company-related figure available for the week is Relfydess authorization in more than 35 markets worldwide, as stated in Galderma’s October 23, 2026, release.
Chronology of the week
On October 23, 2026, Galderma reported China’s approval of Relfydess. The company said the treatment was already authorized in more than 35 markets.
Dates of the coming week
The next Xetra session is scheduled for October 26, 2026. Galderma’s October 23 announcement said it expects to commercially launch Relfydess in China in the second half of 2027.
